NASDAQ: LGND

Ligand Pharmaceuticals (LGND) Stock Analysis & Forecast

Nov 13 close

$308.79−7.48 (−2.4%)

Gekko Brief

AI summaryNov 9 close

Ligand Pharmaceuticals draws attention this week as an insider sale and two Form 144 filings sit alongside continued commentary on the company's growth story. An analyst piece points to Filspari's 85% year-over-year royalty growth and the new FSGS indication as the lead earnings driver, while XOMA's $12.3 million Q3 royalty contribution is cited as adding diversification and pipeline depth, with a BUY rating attached to that view.

Shares close at $314.15, up 2.6%, sitting above both the 50-day average of $299.49 and the 200-day average of $255.99, with the 50-day above the 200-day. The GekkoIndex reads 56.2, placing LGND in the Neutral zone, up 2.1 over five sessions. Price stands 9.2% above Gekko Fair Value of $287.79. The one-year return is 50.9%, with 42.5% over six months and 4.1% over the past month, against a 52-week range of $175.89 to $326.63.

The next earnings report is scheduled for 25 February 2027, 107 days out, placing it beyond a typical 20-trading-day stretch; the prior report on 6 August 2026 showed EPS of $2.37 against a $2.01 estimate, with a -3.1% reaction. Seasonality over five years shows an average 20-day gain of 3.5% from this point, rising in 4 of those years. No insider, Congress or unusual options activity is recorded in their respective windows, leaving the consensus among 9 covering firms, all rated buy with a $350.92 target, as the notable external marker to watch.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Ligand Pharmaceuticals price vs fair value

$308.79$294.94Nov ’25May ’26Nov ’26
Close $308.79200-day averageGekko Fair Value $294.94

Ligand Pharmaceuticals quick facts

Market cap
$6.18B
P/E ratio
127
Forward P/E
25.6
EPS, TTM
$2.49
Revenue, TTM
$253.8M
Profit margin
20.3%
Dividend yield
—
Beta
1.03
Volume
129,021 avg 212,810
1-year return
+50.2%
Typical daily move
±3.9%
Typical 20-day move
±7.1%
50-day average
$301.71
200-day average
$258.37
Next earnings
Feb 25
Shares outstanding
20.00M
52-week range
$175.89$326.63

Ligand Pharmaceuticals swing-trade checklist

Ligand Pharmaceuticals scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $308.79 is above the 50-day ($301.71) and 200-day ($258.37) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    57, Neutral

    Reading 57 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    4.7% above

    Price is within 5% of Gekko Fair Value (4.7% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −5.0% on average

    From this point in the calendar, the next 20 trading days averaged −5% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Ligand Pharmaceuticals stock chart and price history

Ligand Pharmaceuticals closed at $308.79 on Nov 13, 2026, +50.2% over the past year, inside a 52-week range of $175.89 to $326.63.

Close50-day average200-day averageVolume
Ligand Pharmaceuticals share price, past year, with 50-day and 200-day moving averages and volume$150$200$250DecJan 2026FebMarAprMayJunJulAugSepOctNov308.79

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+3.4%
3 months
+5.8%
6 months
+44.8%
1 year
+50.2%
The full LGND chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LGND in Gekko

Follow Ligand Pharmaceuticals through every session

Put LGND on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track LGND in GekkoFree for 7 days. No credit card required.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals works with drugmakers around the world, supplying technologies and materials that support the discovery and development of new medicines. The company is closely associated with Captisol, a proprietary formulation technology it supplies directly and which underpins several products used across its partnerships. Its name is tied to treatments spanning blood cancers, infectious disease, bone health and other conditions, reflecting the breadth of the therapies it has helped bring to market.

Ligand's commercialized products cover a wide medical range, including therapies for multiple myeloma and leukemia, COVID-19 and pneumococcal disease, osteoporosis, postpartum depression, autoimmune disorders, breast cancer and hypertension, among others. Beyond these marketed products, the company takes part in numerous partnered programs still in clinical development, addressing cancer, seizure disorders, diabetes, cardiovascular disease, muscle wasting, and hepatic and renal conditions. Its role centers on enabling other pharmaceutical companies' research and product development rather than solely marketing medicines under its own name.

Founded in 1987, Ligand Pharmaceuticals is based in Emeryville, California. Its shares trade on the NASDAQ under the ticker LGND.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
ligand.com

Ligand Pharmaceuticals GekkoIndex: the smart money zone

Ligand Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57, in the Neutral zone, down 0.9 points over five sessions.

010057Neutral

Down 0.9 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying2Too few readings yet
Accumulation163+2.5%+4.9%+8.5%+15.9%
Neutral (current zone)452+0.9%+1.5%+3.8%+12.1%
Distribution75−0.2%+2.3%+2.4%+6.9%
Selling10+1.6%+0.6%−2.0%0.0%

Average LGND share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the LGND price, zone by zone.Track LGND in Gekko

Is Ligand Pharmaceuticals stock overvalued? Gekko Fair Value

Ligand Pharmaceuticals trades 4.7% above Gekko Fair Value of $294.94, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Ligand Pharmaceuticals shares are worth, recalculated every trading day.

$294.94

Gekko Fair Value, Nov 14, 2026

4.7% above fair value · About fair value

At the end of Aug 2026 the price was 13.1% below the estimate.

Gekko Fair ValueShare price, month end
$295$309Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open LGND in Gekko

Ligand Pharmaceuticals insider and Congress trading

No open-market insider purchases were filed for Ligand Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for LGND in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every LGND insider filing, plotted on the chart in Gekko.Open LGND in Gekko

Congress trades last 90 days

No trades in LGND were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for LGND, plotted on the chart in Gekko.Open LGND in Gekko

Buybacks

Ligand Pharmaceuticals has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$60.00M
As a share of market cap
0.97%

From company filings.

Ligand Pharmaceuticals earnings: next date and track record

Ligand Pharmaceuticals reports on Feb 25, 2027 (102 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±4.2%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+3.7%Nov ’24+6.3%Feb ’25−1.1%May ’25+5.4%Aug ’25+6.4%Nov ’25+3.6%Feb ’26−3.6%May ’26−3.1%Aug ’26

Last earnings call, Aug 6, 2026 AI summary

What they said
Ligand reported Q2 2026 royalty revenue up 32% year-over-year with adjusted EPS growing 48%, reflecting broad-based portfolio growth. The company closed the XOMA Royalty acquisition post-quarter, adding 120+ commercial, clinical, and preclinical assets while nearly doubling its late-stage pipeline. A $700 million zero-coupon convertible offering was completed to fund growth initiatives. Management emphasizes the XOMA deal diversifies rather than concentrates risk, extending cash flows through 2040.
Guidance
XOMA acquisition expected to contribute ~$0.50 adjusted EPS in H2 2026 and ~$1.50 in 2027, with meaningful growth beyond that. Management maintains an active business development pipeline supported by the strengthened balance sheet.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026$2.37
est $2.01
+17.9%$63.69M
est $61.30M
+3.9%−3.1%
May 14, 2026$1.63
est $1.84
−11.4%$51.72M
est $59.10M
−12.5%−3.6%
Feb 26, 2026$2.02
est $1.46
+38.4%$59.67M
est $55.59M
+7.3%+3.6%
Nov 6, 2025$3.09
est $1.97
+56.9%$115.5M
est $55.59M
+107.7%+6.4%
Aug 7, 2025$1.60
est $1.42
+12.7%$47.63M
est $43.87M
+8.6%+5.4%
May 8, 2025$1.33
est $1.21
+9.9%$45.33M
est $38.71M
+17.1%−1.1%
Feb 27, 2025−$1.64
est $1.37
−219.7%$42.81M
est $39.03M
+9.7%+6.3%
Nov 7, 2024−$0.39
est $0.75
−152.0%$51.81M
est $39.01M
+32.8%+3.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Ligand Pharmaceuticals stock forecast and analyst price targets

Analysts’ average 12-month price target for Ligand Pharmaceuticals is $361.27, +17.0% from the last close, from 9 firms rating the stock in the last 90 days.

$361.27consensus 12-month target, +17.0% from the last close
Low $346High $406
Buy9
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 9 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12H.C. WainwrightBuy, reiterated$358+15.9%
Nov 11BarclaysBuy, reiterated$350+13.3%
Nov 5CitiBuy, maintained$402+30.2%
Nov 2Leerink PartnersBuy, reiterated$350+13.3%
Nov 1RBC CapitalBuy, reiterated$357+15.6%
+3.8%average 20-day move after past Neutral readings
−5.0%average move over the next 20 trading days in the last 5 years
±3.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Ligand Pharmaceuticals seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Ligand Pharmaceuticals averaged −5.0% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−12.8%2021−20.3%2022+19.1%2023+1.3%2024−4.0%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.3%2 of 5
Next 10 trading days−2.2%2 of 5
Next 15 trading days−4.4%2 of 5
Next 20 trading days−5.0%1 of 5
Next 30 trading days−1.3%1 of 5

For scale, LGND’s typical 20-trading-day move in either direction is about 7.1%.

Ligand Pharmaceuticals market cap and key statistics

Ligand Pharmaceuticals’s market cap is $6.18B, with a P/E ratio of 127 and revenue of $253.8M over the last twelve months.

Valuation

Market cap
$6.18B
P/E ratio
127
Forward P/E
25.6
EPS, TTM
$2.49
Gekko Fair Value
$294.94

Trading

Volume
129,021
Avg volume, 20 days
212,810
52-week high
$326.63
52-week low
$175.89
Shares outstanding
20.00M

Financials

Revenue, TTM
$253.8M
Profit margin
20.3%
Return on equity
5.4%
Quarterly earnings growth, YoY
+825.0%

Risk and income

Beta
1.03
Typical daily move
±3.9%
Typical 20-day move
±7.1%

Ligand Pharmaceuticals peers

Ligand Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Ligand Pharmaceuticals stock FAQ

What is Ligand Pharmaceuticals’s market cap?

Ligand Pharmaceuticals’s market cap is $6.18B at the Nov 13, 2026 close of $308.79, with 20.00M shares outstanding. The shares trade on a P/E ratio of 127.

What is the Ligand Pharmaceuticals stock forecast?

The consensus analyst 12-month price target for Ligand Pharmaceuticals is $361.27, +17.0% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Ligand Pharmaceuticals stock overvalued or undervalued?

On Gekko’s estimate Ligand Pharmaceuticals is about fair value: the Nov 13, 2026 close of $308.79 is 4.7% above Gekko Fair Value of $294.94. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Ligand Pharmaceuticals report earnings next?

Ligand Pharmaceuticals is expected to report on Feb 25, 2027 (102 days away). Analysts expect earnings of $2.84 per share on revenue of $97.80M. Ligand Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 4.2% on average across the report.

What is Ligand Pharmaceuticals’s 52-week high and low?

Ligand Pharmaceuticals’s 52-week high is $326.63 and its 52-week low is $175.89; it closed at $308.79 on Nov 13, 2026, +50.2% over the past year.

Is Ligand Pharmaceuticals stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Ligand Pharmaceuticals the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.